TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01605071

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estradiol
Description: 1 week of transdermal estradiol (0.15mg)~1 week of transdermal placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estradiol
Description: 1 week of transdermal estradiol (0.15mg)~1 week of transdermal placebo
Study: NCT04258631

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liposomal Bupivacaine
Description: Drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Bupivacaine
Description: Drug
Study: NCT02424955

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: perflutren lipid microspheres

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 3D ultrasound
Study: NCT04258631

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT03331354

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Distant vocational learning
Description: use of hybrid distance learning to facilitate successful employment outcomes

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Basic vocational services
Description: self-help manual
Study: NCT04025957

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1501
Description: Administered subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1501
Description: Administered subcutaneously
Study: NCT02898610

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchicine
Study: NCT04051021

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Comfort Coach
Description: A trained comfort coach will provide emotional and psychological interventions at six time points: preoperative clinic, day of surgery, extubation, chest tube removal, discharge, 30-day clinic follow-up, and 90-day post-discharge. Patients will also complete surveys at specific time points (preoperative clinic, hospital discharge, 30-day clinic follow-up, and 90-day post-discharge).
Study: NCT03044054

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ECHOPULSE
Description: HIFU Under ultrasound guidance
Study: NCT04639726

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Whey Protein Micro Gel
Description: The test product is whey protein microgels 10g, reconstituted in 125ml water.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Water without Whey Protein.
Description: A matching placebo (125ml of water without whey protein) will be used as control.
Study: NCT01923038

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: First arm: patients ventilated with zero end expiratory pressure

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Patients ventilated with Positive End Expiratory Pressure

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Patients ventilated with Positive End Expiratory Pressure plus Recruitment maneuver
Study: NCT01600651

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Recruitment Maneuver (RM) sham group
Description: It 's when RM sequence precedes a shame evaluation period

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham recruitment maneuver (RM) group
Description: Group in which patients receive a sham sequence before the RM sequence
Study: NCT03132987

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Progressive strengthening program
Description: The progressive strengthening program will be performed for 3 weeks and emphasize development of strength and power. Feasibility will be established if we can recruit up to 8 participants and retain at least 80% over the 3 week intervention program. We will determine effect sizes for changes outcome measures.
Study: NCT01181908

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: single dose
Description: Subjects will receive a single dose of GSK1144814 or placebo.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: single dose
Description: Subjects will receive a single dose of GSK1144814 or placebo.
Study: NCT04051021

Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: Patients will complete surveys at specific time points (preoperative clinic, hospital discharge, 30-day clinic follow-up, and 90-day post-discharge).
Study: NCT03613415

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Expansion
Description: non invasive technique to increase thickness of thin ridge

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Expansion
Description: non invasive technique to increase thickness of thin ridge
Study: NCT00206999

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imipramine
Description: Either 50 mg of imipramine or placebo will be administered to healthy male volunteers
Study: NCT04080154

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: 12mg orally (p.o.) every day (qd) for 2 weeks of every 3 week cycle (i.e. 2 weeks on, 1 week off)
Study: NCT01543464

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy: Temozolomide
Description: Vaccine: 250 microgram IDO5 peptide + 250 microgram Survivin peptide + 500 microL Montanide every 2nd week Adjuvants: 75 microgram GM-CSF + 1 application Imiquimod every 2nd week
Study: NCT03649958

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HIRREM-SOP or Cereset
Description: HIRREM-SOP for ten 90 minute sessions

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cereset 2x
Description: Cereset 2x for five 90 minute sessions
Study: NCT02951611

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture stimulation
Description: Transcutaneous electrical acupoint stimulation on SI3, SJ6, PC6 and LI4

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham stimulation
Description: Put electrodes on SI3, SJ6, PC6 and LI4 without stimulation
Study: NCT04649528

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Effective endurance 4x4 training - Supervised
Description: Exercise intervention utilizing 4x4min aerobic high-intensity interval training

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Effective endurance 4x4 training - APP
Description: Exercise intervention utilizing 4x4min aerobic high-intensity interval training
Study: NCT04228978

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight loss
Description: Walking exercise combined with weight loss

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Walking exercise

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Walking exercise
Study: NCT02462486

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abicipar Pegol
Description: Abicipar pegol intravitreal injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abicipar Pegol
Description: Abicipar pegol intravitreal injection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab
Description: Ranibizumab intravitreal injection.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sham Procedure
Description: Sham injection.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sham Procedure
Description: Sham injection.
Study: NCT00220727

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immune Globulin IV [Human], 10% Caprylate/Chromatography Purified
Description: IGIV-C 10% at a dose of 1.0g/kg was to be given on 2 occasions as a single daily infusion: Group 1 were to receive their first IGIV-C, 10-% infusion at a rate of 0.08 mL/kg/min and a second infusion at 0.14 mL/kg/min. and Group 2 were to receive their first IGIV-C, 10-% infusion at a rate of 0.14 mL/kg/min and a second infusion at a rate of 0.08 mL/kg/min.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immune Globulin IV [Human], 10% Caprylate/Chromatography Purified
Description: IGIV-C 10% at a dose of 1.0g/kg was to be given on 2 occasions as a single daily infusion: Group 1 were to receive their first IGIV-C, 10-% infusion at a rate of 0.08 mL/kg/min and a second infusion at 0.14 mL/kg/min. and Group 2 were to receive their first IGIV-C, 10-% infusion at a rate of 0.14 mL/kg/min and a second infusion at a rate of 0.08 mL/kg/min.
Study: NCT03097939

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: 1 mg/kg of IV Ipilimumab is admistered over 90 minutes every 6 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 3 mg/kg of IV Nivolumab is administered over 30 minutes every 2 weeks
Study: NCT02809768

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avatrombopag

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avatrombopag

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avatrombopag

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluconazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Study: NCT02111434

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone
Description: Testosterone 250 mg injection per 3-4 weeks for 6 months
Study: NCT01999894

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine HCl
Description: Memantine extended release 3- and 6-mg capsules; dose ranging 3 - 18 mg/day; weight based dosing in 4 weight groups; oral administration. Dosing is once daily for 48 weeks.
Study: NCT00006228

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: Given IV
Study: NCT03214315

Intervention type: PROCEDURE
Intervention: Visceral adipose tissue specimen
Description: specimen
Study: NCT03047655

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle intervention (physical activity)
Description: Dietary treatment with or without additional motivation on more physical activity

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle intervention (physical activity)
Description: Dietary treatment with or without additional motivation on more physical activity

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle intervention (PUFA/isomaltulose-enriched muffin)
Study: NCT02825667

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy sessions
Description: Physiotherapy by techniques myofascial therapy, in patients with ankle hemophilic arthropathy
Study: NCT04280588

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fingolimod 0.5 mg
Description: Each patient in the fingolimod treatment group was given 0.5 mg of fingolimod orally once daily, for three consecutive days
Study: NCT03960944

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga
Description: 30 Min Yoga session included of Physical posture, Breathing exercise, Yoga games and Relaxation.
Study: NCT04102566

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen 600 mg
Description: We'll be adding ibuprofen while trying to limit oxycodone use while hospitalized. Patients will not be discharged with a narcotic.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: We'll be adding education to patient's post-operative instructions to aid in their pain control management.
Study: NCT00279695

Intervention type: PROCEDURE
Intervention: high frequency ultrasound examination
Description: high frequency ultrasound examination of the eye

Intervention type: PROCEDURE
Intervention: high frequency ultrasound examination
Description: high frequency ultrasound examination of the eye

Intervention type: PROCEDURE
Intervention: high frequency ultrasound examination
Description: high frequency ultrasound examination of the eye

Intervention type: PROCEDURE
Intervention: high frequency ultrasound examination
Description: high frequency ultrasound examination of the eye
Study: NCT02038647

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alisertib
Description: Alisertib tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel intravenous injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel intravenous injection
Study: NCT05931822

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Silver Diamine Fluoride 38%
Description: silver diamine fluoride 38% brushed on the cavity for 1 minute before adding high viscosity glass ionomer restoration in one molar

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: fluoride varnish
Description: fluoride varnish brushed after adding the high viscosity glass ionomer restoration in the contralateral molar
Study: NCT00834782

Intervention type: PROCEDURE
Intervention: IOP measurement
Description: Measuring IOP
Study: NCT00593619

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iron dextran
Description: 300mg in 250cc normal saline given over 2 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iron sucrose
Description: 300mg in 250cc normal saline given over 2 hours
Study: NCT04576559

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified dental visual aids
Description: Modified Dental visual aids in the form of pictures created by the main investigator

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Regular dental visual aids
Description: Regular dental visual aids
Study: NCT01148888

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium
Description: Magnesium will be administered intravenously at a dose of 50 mg/kg bolus followed by an infusion of 10 mg/kg/hr.
Study: NCT02960152

Intervention type: OTHER
Intervention: diagnostic
Description: full-mouth periodontal examination

Intervention type: OTHER
Intervention: diagnostic
Description: full-mouth periodontal examination

Intervention type: OTHER
Intervention: diagnostic
Description: full-mouth periodontal examination
Study: NCT02017418

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: zeaxanthin
Description: softgel

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: combinatory supplement
Description: softgel
Study: NCT02697487

Intervention type: OTHER
Intervention: No treatment
Description: This is an observational study with no intervention.
Study: NCT01982565

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NOx dressing
Description: The NOx dressing should be changed at least every 2 days.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: The clinician/podiatrist is free to use whichever treatment they would choose to use on the patient in their current clinical practice.
Study: NCT00827528

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional correction of anterior vaginal wall prolapse
Description: Traditional repair.~Patients diagnosed with anterior vaginal wall prolapse will be submitted to surgical correction. They will be randomized to receive a traditional repair or a graft in surgery.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biologic Graft (SIS)
Description: Biologic graft (SIS - Small Intestine Submucosa) in correction of anterior vaginal wall prolapse.~Patients diagnosed with anterior vaginal wall prolapse will be submitted to surgical correction. They will be randomized to receive a traditional repair or a graft in surgery.
Study: NCT00875979

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab emtansine [Kadcyla] 3.0 mg/kg
Description: Trastuzumab emtansine was provided as a single-use lyophilized formulation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab emtansine [Kadcyla] 3.6 mg/kg
Description: Trastuzumab emtansine was provided as a single-use lyophilized formulation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab 420 mg
Description: Pertuzumab was provided as a single-use formulation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab 420 mg
Description: Pertuzumab was provided as a single-use formulation.
Study: NCT01068834

Intervention type: GENETIC
Intervention: KIF6 genetic test
Description: KIF6 carrier status with interpretation sheet provided to subject
Study: NCT01845142

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: single administration of 100.000 I.U. vitamin D

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: single administration of 100.000 I.U. vitamin D

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02016001

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: toothpaste 1 with maximum fluoride concentration
Description: tooth paste 1 will be the tested intervention with maximum fluoride concentration (1500 ppm), which will be provided to the case group. They will brush the teeth twice daily for 2 minutes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: toothpaste 2 with 1000 ppm of fluoride
Description: tooth paste 2 will be the intervention with 1000ppm of fluoride, will be used by the control group. They will brush the teeth twice daily for 2 minutes
Study: NCT03802695

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OrcaGraft (Orca-Q)
Description: engineered donor allograft

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OrcaGraft (Orca-Q)
Description: engineered donor allograft

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OrcaGraft (Orca-Q)
Description: engineered donor allograft
Study: NCT01865097

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relaxation guided imagery
Description: An individualized relaxation guided imagery session will be conducted. After the session patients will be given a CD with the relaxation guided imagery and asked to listen to it at home.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Relaxing music
Description: An individualized session of listening to relaxing music will be conducted. After the session patients will be given a CD with the relaxing music and asked to listen to it at home.
Study: NCT01248208

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FluMist intranasal influenza vaccine
Description: FluMist intranasal vaccine 0.2 mL will be given 0.1 mL in each nostril per manufacturer's instructions.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Intramuscular influenza injection (flu shot)
Description: Subjects \< 2 years or \> 49 years or those with asthma symptoms or treatment within the past year will receive the intramuscular flu shot in a single injection.~Age 6-36 months: 0.25 mL IM x 1; Age \>36 months: 0.5 mL IM x 1 Boosters: All children aged 6 months-8 years who receive a seasonal influenza vaccine for the first time should be administered 2 doses. Children aged 6 months-8 years who received a seasonal vaccine for the first time during 2009-2010 but who received only 1 dose should receive 2 doses, rather than 1, during 2010-2011. In addition, for the 2010-11 influenza season, children aged 6 months-8 years who did not receive at least 1 dose of an influenza A (H1N1) 2009 monovalent vaccine should receive 2 doses of a 2010-11 seasonal influenza vaccine, regardless of previous influenza vaccination history. For all children, the second dose of a recommended 2-dose series should be administered 4 or more weeks after the initial dose.
Study: NCT00705926

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Highly Active Antiretroviral Therapy (HAART)
Description: Participants in Groups A1 and A2 will receive HAART for either 12 or 32 weeks. Their medications will not be provided by the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Highly Active Antiretroviral Therapy (HAART)
Description: Participants in Groups A1 and A2 will receive HAART for either 12 or 32 weeks. Their medications will not be provided by the study.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No treatment
Description: Participants in this group will not receive treatment at this stage of their infection.
Study: NCT03656770

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey questionnaire
Description: Each version of the questionnaire portrays a young Ugandan woman with different profiles of illness severity, treatment, and treatment response.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey questionnaire
Description: Each version of the questionnaire portrays a young Ugandan woman with different profiles of illness severity, treatment, and treatment response.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey questionnaire
Description: Each version of the questionnaire portrays a young Ugandan woman with different profiles of illness severity, treatment, and treatment response.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey questionnaire
Description: Each version of the questionnaire portrays a young Ugandan woman with different profiles of illness severity, treatment, and treatment response.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey questionnaire
Description: Each version of the questionnaire portrays a young Ugandan woman with different profiles of illness severity, treatment, and treatment response.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey questionnaire
Description: Each version of the questionnaire portrays a young Ugandan woman with different profiles of illness severity, treatment, and treatment response.
Study: NCT03795519

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-olinciguat
Description: oral capsule
Study: NCT03170986

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multisectoral agriculture and Microfinance Intervention
Study: NCT03951480

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual medicine
Description: At a rate of 3 sessions of a maximum of 30 minutes each at one week interval. Depending on the clinical evolution, it is possible to stop manual medicine sessions according to the therapist's assessment as in current practice. If the patient has an EVA pain of activity \< 2, manipulations will not be continued. The patient being considered as not very symptomatic.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroids infiltration
Description: A unique echo-guided infiltration of one syringe of 1 mL of cortisone product
Study: NCT03656770

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey questionnaire
Description: Each version of the questionnaire portrays a young Ugandan woman with different profiles of illness severity, treatment, and treatment response.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey questionnaire
Description: Each version of the questionnaire portrays a young Ugandan woman with different profiles of illness severity, treatment, and treatment response.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey questionnaire
Description: Each version of the questionnaire portrays a young Ugandan woman with different profiles of illness severity, treatment, and treatment response.